wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

Khan - Obesity

Total questions: 40

Worksheet time: 40mins

Name
Class
Date
1.

Therapeutic agents: Centrally acting

a)

GLP-1 agonists

b)

Phentermine

c)

Phentermine topiramate ER

d)

Naltrexone Bupropion

e)

Setmelanotide

2.

Therapeutic agents: Centrally acting --> short term

a)

GLP-1 agonists

b)

Phentermine

c)

Phentermine topiramate ER

d)

Naltrexone Bupropion

e)

Setmelanotide

3.

Therapeutic agents: Peripherally acting

a)

GLP-1 agonists

b)

Orlistat

c)

Famotidine

d)

Naltrexone Bupropion

4.

Overweight BMI

a)

25-29.9 kg/m2

b)

> 30 kg/m2

5.

Obese BMI

a)

25-29.9 kg/m2

b)

> 30 kg/m2

6.

GOAL for overweight and obesity

a)

Increase calories

b)

Decrease Calories

c)

Increase energy expenditure

d)

BOTH

e)

Eat subway at least one weekly

7.

Risk factors to consider for overweight and obesity

a)

CAD, HTN, dyslipidemia

b)

Type ll diabetes and stroke

c)

sleep apnea and depressions

d)

infertility

e)

Allergies

8.

For treat obesity

a)

Drug therapy

b)

dietary plan

c)

physical activity

d)

just dietary plan

e)

just drug therapy

9.

For treat obesity and overweight: Stimulant drugs --> jump start agent for ____

a)

short term

b)

long term

10.

For treat obesity and overweight: Stimulant drugs --> anti-obesity drugs agent for ____

a)

short term

b)

long term

11.

Agents that can promote weight gain

a)

antipsychotics: clozapine, olanzapine, risperidone, quetiapine

b)

Insulin

c)

Sulfonylureas

d)

TZD

e)

Lithium

12.

Agents that can promote weight gain

a)

Valproic acid

b)

gabapentin

c)

pregabalin

d)

mirtazapine, amitriptyline, nortriptyline

e)

Orlistat

13.

Inhibits GI lipase --> decrease dietary fat (triglyceride) absorption (plus a low-fat diet)

a)

Valproic acid

b)

gabapentin

c)

pregabalin

d)

Orlistat

14.

ADRs: GI (fatty stool, intestinal gas with discharge, increase number of bowel movement)

a)

Valproic acid

b)

gabapentin

c)

pregabalin

d)

Orlistat

15.

C/l: pregnancy, malabsorption

a)

Valproic acid

b)

gabapentin

c)

pregabalin

d)

Orlistat

16.

Decrease absorption of fat-soluble vitamins (ADEK), decrease cyclosporine and decrease levothyroxine absorption --> take separately

a)

Valproic acid

b)

gabapentin

c)

pregabalin

d)

Orlistat

17.

____ functions:

-Increases insulin synthesis and release

-Lowers glucagon release --> reduced hepatic glucose production

-Slows gastric emptying

-Stimulates GLP-1 receptor in the hypothalamus --> decrease food intake

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

18.

SC injection

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

19.

Liraglutide, semaglutide

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

20.

Binds to and activate receptors --> G-protein coupled receptor

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

21.

Boxed warnings: Risks of thyroid C cell carcinoma, contraindicated in MEN (multiple endocrine neoplasia)

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

22.

ADRs: Hypoglycemia, pancreatitis, nausea

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

23.

ADRs: Tachycardia, elevated HR, elevated BP, insomnia

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

24.

Short-term use (up to 12 weeks)

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

25.

Contraindications: uncontrolled hypertension, hyperthyroidism, pregnancy

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

26.

Sympathomimetic agent

-Increase norepinephrine release

-Decrease NE reuptake from the synapse

-Increases NE in the hypothalamus --> decrease appetite

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

27.

ADRs: tachycardia, vision problems, insomnia

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

28.

C/l: pregnancy, glaucoma, hyperthyroidism

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

29.

Drug interactions: MAOI and phentermine --> hypertensive crisis

a)

GLP-1 agonists

b)

Phentermine topiramate extended release

c)

Phentermine

d)

Orlistat

30.

Setmelanotide

a)

Peptide analog of endogenous alpha-MSH

b)

Melanocyte stimulating hormones MSHs act by their specific interactions with five melanocortin receptor (MCR) subtypes (MC1R-MC5R)

c)

MCRs (MC1R-MC5R) are G-protein coupled receptors

d)

Setmelanotide activates MC4 receptor in the brain --> decrease hunger and promote weight loss

e)

ADRs: injection site reaction, hyperpigmentation, HA, GI ADRs

31.

Phentermine topiramate extended release:

-Migraine, epilepsy

-Weight loss --> undesirable effect

a)

Phentermine

b)

Topiramate

32.

Phentermine topiramate extended release:

Teratogenic, increases the risk of congenital fetal oral-cleft formation (negative pregnancy test needed before treatment and monthly thereafter)

a)

Phentermine

b)

Topiramate

33.

Phentermine topiramate extended release:

Taper off due to seizure risk from _____ (rebound phenomenon)

a)

Phentermine

b)

Topiramate

34.

Naltrexone bupropion extended release: Naltrexone

a)

Opioid antagonist

b)

Alcohol and opioid dependence

c)

Reuptake inhibitor of NE and dopamine

d)

Depression and smoking cessation

35.

Naltrexone bupropion extended release: Bupropion

a)

Opioid antagonist

b)

Alcohol and opioid dependence

c)

Reuptake inhibitor of NE and dopamine

d)

Depression and smoking cessation

36.

Naltrexone bupropion extended release: _____ stimulates release of alpha-melanocyte stimulating hormone (alpha-MSH) from pro-opiomelanocortin (POMC) in the hypothalamus

a)

Bupropion

b)

Naltrexone

37.

Naltrexone bupropion extended release: alpha-MSH

a)

decreases food intake

b)

increases food intake

38.

Boxed warnings: suicidal thinking and behavior (bupropion)

a)

Naltrexone bupropion extended release

b)

phentermine

c)

phentermine topiramate extended release

d)

Setmelanotide

39.

Naltrexone bupropion extended release contraindications

a)

Pregnancy

b)

Uncontrolled hypertension

c)

Chronic opioid use

d)

Seizure disorder

e)

During and within 14 days of taking MAOIs

40.

Naltrexone bupropion extended release --> bupropion

a)

Pregnancy

b)

Uncontrolled hypertension

c)

Chronic opioid use

d)

Seizure disorder

e)

During and within 14 days of taking MAOIs